Clinical research on the effects of rhIL-11 in preventing and curing thrombocytopenia caused by chemotherapy .
- VernacularTitle:基因重组人白细胞介素-11防治化疗所致血小板减少的临床研究
- Author:
Xiaodong XIE
;
Zhendong ZHENG
;
Dawei LIU
- Publication Type:Journal Article
- Keywords:
Recombinant human interleukin 11;
Thrombocytopenia;
Chemotherapy
- From:
Chinese Journal of Practical Internal Medicine
2001;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To Observe both curative and side effects of rhIL-11(recombinant human interleukin 11)in preventing and curing thrombocytopenia caused by chemotherapy.Methods From May 2003 to May 2004,research was done in the Department of Oncology,General Hospital of Shenyang Military Region by adopting double-blind placebo contrast and self cross-over study methods on 42 non-small cell lung cancer patients who had received GC chemotherapy.The effects of rhIL-11 and placebo on the minimal number of thrombocytes and their toxins were compared.24 hours later after the medicine for chemotherapy was given,rhIL-11 was administered hypodermically to the patients at the amount of 25 ?g/kg for 7 to 14 days.When the thrombocyte number was higher than 300?10~9/L,the administration of rhIL-11 was stopped.Results RhIL-11 could obviously increase the minimal number of thrombocytes during chemotherapy and reduce the times for blood transfusion.The side of rhIL-11 were mild edema,weariness and symptoms of catching cold.Conclusion RhIL-11 plays an obvious role in preventing and curing thrombocytopenia caused by chemotherapy,and has safe and definite curative effects without serious effects.
